• Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification (Ro-SjS)

  NCT07414667

  Not yet recruitingObservationalUpdated Feb 17, 2026
• Interstitial Pneumonia With Autoimmune Features: Evaluation of Connective Tissue Disease Incidence During Follow-up

  NCT04179058

  Unknown statusObservationalUpdated Nov 26, 2019
• Evaluation of Interstitial Lung Disease Severity in Patients With Antisynthetase Syndrome According to Specific Autoantibodies Profile

  NCT04924465

  Unknown statusObservationalUpdated Jun 14, 2021
• Connective Tissue Diseases and Lung Manifestations

  NCT04095351

  RecruitingObservationalUpdated May 27, 2020
• Follow-up Study of Individuals with Autoantibodies Against Ro/SSA and La/SSB

  NCT06594861

  RecruitingObservationalUpdated Sep 19, 2024
• Ro60 Expression in Macrophages in Sjogren's Disease

  NCT06324968

  Active, not recruitingInterventionalNot ApplicableUpdated Mar 11, 2025

ClinicalTrials.gov ID

NCT03565601

Lead Sponsor

Central Hospital, Nancy, FranceOTHER

Overall Status

Unknown status

Study Type

Observational

Enrollment

400Estimated

Last Update Posted

Dec 9, 2019Actual

Start Date

Jan 1, 2019Actual

Primary Completion Date

Sep 1, 2020Estimated

Completion Date

Sep 1, 2020Estimated

Official Title

Phenotypic Features and Prognostic Value of Anti-Ro52 (TRIM-21) Antibodies in Connective Tissue Diseases

Brief Summary

Anti-Ro52 autoantibodies can be detected in patients with several autoimmune diseases. Clinical significance of anti-Ro52 is controversial. The presence of anti-Ro52 may be a factor associated with disease severity (interstitial lung disease, vasculopathy) and cancers. The aim of this study is to assess interstitial lung disease and vasculopathy prevalence and severity, cancers occurence and others clinical features of connective tissue disease patients with anti-Ro52 autoantibodies.

• Connective Tissue Diseases

• Follow-up

Ages Eligible for Study

Child (0-17)Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Connective tissue disease (differenciated or not)
• Presence of anti-Ro52 antibodies at diagnosis

Exclusion Criteria:

• Healthy subjects

Observational Model

Case-Control

Time Perspective

Retrospective

Lead Sponsor

Central Hospital, Nancy, FranceOTHER

francois.maurier@hp-metz.fr